Genzyme Fabrazyme
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company presented results of its pivotal Phase III study in 58 patients with Fabry disease at the American Society of Human Genetics meeting in Philadelphia Oct. 5. Twenty of 29 patients treated every two weeks for 20 weeks with intravenous agalsidase beta achieved a score of zero on a scale of 0-3 measuring the level of GL-3 in the kidney vasculature. The score indicated that patients' "blood vessels were restored to a near normal state," providing "strong evidence that the kidney should function normally as a result of treatment," the company said. Genzyme expects approval for its BLA, submitted June 23, around the end of the yea
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.